Understanding & Conquering Depression | Huberman Lab Podcast #34

Psychedelics

Psychedelic substances like psilocybin are gaining attention in clinical studies for their potential to treat depression. Andrew Huberman highlights that while these substances remain illegal in most places, controlled studies show promising results. Psilocybin, in particular, has shown significant improvement in mood and relief from depressive symptoms in 50-70% of study participants 1.

Psilocybin engages or increases serotonin transmission, meaning it increases the amount of serotonin, mainly by acting at these 5H2A receptors.

--- Andrew Huberman

These studies are conducted in highly controlled environments, emphasizing the importance of trained guides and medical monitoring 2.

   

NMDA Receptors

The NMDA receptor plays a crucial role in novel treatments for depression, particularly with compounds like ketamine. Andrew Huberman explains that ketamine creates dissociative states, which can help patients distance themselves from depressive narratives 3. This effect is linked to the activation of layer five in the cortex, enhancing lateral connectivity between brain areas 4.

It's somehow rewiring associations between events, emotional events, past events, current events, and future events in ways that allow people to get some sort of relief.

--- Andrew Huberman

These findings suggest a potential for ketamine to offer new perspectives and optimism for those suffering from depression.